Can CVS Health Maintain Its Growth Through the End of 2025?

CVS Health is experiencing a significant rebound, with shares up 77% this year, driven by strong Q3 results including a 7.8% revenue increase to $102.9 billion and a 47% jump in non-GAAP EPS, leading to increased FY2025 guidance. The company is implementing a $2 billion cost-saving plan and strategically exiting unprofitable segments like parts of Medicare Advantage and the ACA market to enhance profitability. Despite recent gains, its 10.7x forward P/E ratio remains attractive compared to the industry average, positioning CVS for continued momentum and long-term growth, supported by an aging population and its integrated healthcare ecosystem.

Analysis

CVS Health has demonstrated a significant financial rebound, with shares appreciating 77% this year. This performance is underpinned by robust Q3 results, including a record revenue of $102.9 billion, marking a 7.8% year-over-year increase, and a substantial 47% rise in non-GAAP earnings per share to $1.60. Adjusted operating income also surged 35.8% year-over-year to $3.5 billion, leading to an increased fiscal year 2025 guidance.

The company's turnaround is largely attributed to strategic initiatives aimed at improving profitability. CVS is implementing a plan to achieve at least $2 billion in cost savings and is actively exiting unprofitable segments, such as parts of its Medicare Advantage business and the Affordable Care Act's health insurance market. These actions, while potentially impacting overall revenue, are expected to drive stronger top- and bottom-line growth in the near to medium term.

Despite its recent rally, CVS Health's valuation remains attractive, trading at 10.7 times forward earnings compared to the healthcare industry average of 17.1. This valuation, combined with its integrated healthcare ecosystem, strong competitive advantages, and long-term tailwinds from an aging population, positions the company for continued momentum. Furthermore, its 3.4% forward dividend yield and 53.3% cash payout ratio make it appealing for income-focused investors.

Key Decisions for Investors

• Investors should consider CVS Health for its compelling valuation relative to industry peers and its demonstrated financial turnaround driven by strategic cost-cutting and segment optimization.
• Monitor the execution of CVS's $2 billion cost-saving plan and the impact of its exits from less profitable business lines on future revenue and margin expansion.
• Evaluate CVS as a potential long-term holding, given its strong dividend yield, integrated healthcare model, and favorable demographic trends supporting sustained growth in healthcare services.